Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis

View original at nasdaq.com
Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis Key Points Ford Credit is one of the automaker's most profitable units…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Off-lease EV volume will peak in 2028 with nearly 800,000 EVs flooding the market

    60% confidence

  • Industry experts are expecting the resale value of off-lease EVs will check in around $10,000 less than automaker finance entities projected, and could range anywhere from $5,000 to $20,000 less

    60% confidence

  • Stock Advisor's total average return is 914% compared to 184% for the S&P 500

    60% confidence

  • Roughly 228,000 Tesla EVs were leased last year, nearly 102,000 EV leases for General Motors, and a little over 52,000 EV leases for Ford

    60% confidence

  • Using the $10,000 figure, that would be an industrywide loss of about $8 billion for expected models coming off lease in 2028

    60% confidence

  • Ford Motor Company was not among the 10 best stocks for investors to buy now

    60% confidence

  • Ford Credit typically generates only about 5% of revenue any given year but provides 15% to 20%, sometimes more, of the company's profits

    60% confidence

  • EVs expected to make up 15% of off-lease used vehicles by the end of 2026, compared to only 7.7% during the first quarter

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Ford Faces a Profitability Threat It Hasn't Seen Since the 2008 Financial Crisis — Source | Via News | ViaNews EU